arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Design Therapeutics, Inc.

DSGN
$12.38 ▼ -0.79 (-6.00%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
27 Visible periods
23 Metrics
Peer-ranked Benchmarks
Price Chart
31
Health
Poor
Bearish
auto_awesome

Analytical Summary

Design Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $773.8M
Dividend Yield
Revenue Growth
Op. Margin None
ROIC -8.7%
FCF / Share $-0.25
Trailing P/E
Price / Book 3.8x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

27-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
Net Income Profit after all expenses
$-20.16M
↓ -5.7%
FCF / Share Free cash flow per share
$-0.25
↑ +7.0%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
22
Cash Quality
53

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 7 years · 27 quarters